Non-adherence: pharma’s final financial frontierNo other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue. Share XNon-adherence: pharma’s final financial frontierhttps://pharmaphorum.com/views-and-analysis/non-adherence-pharmas-final-financial-frontier/